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Platelets are derived from megakaryocytes; they circulate in 
mammalian blood vessels and play essential roles in hemo-
stasis and thrombosis. When platelets encounter injury, they 
respond by triggering the formation of a blood clot to pre-
vent blood loss (hemostasis). While this is vital for survival, 
platelets can cause blood clots inside arteries (known as 
thrombosis), which can trigger heart attack and stroke. 
Platelets express a variety of receptors, including adhesive 
receptors, such as glycoprotein (GP) IIb-IIIa (IIb3), 
GPIb-IX-V, GPIa-IIa (21), and GPVI, which can mediate 
the adherence of platelets to exposed collagen fibers at  
the sites of blood vessel injury or atherosclerosis plaque 
rupture [1]. These adhesive receptors initiate intracellular 
signals that cause platelet adhesion, spreading, and secre-
tion. The activated platelets release several soluble agonists, 
such as adenosine diphosphate (ADP), prostanoid throm-
boxane A2 (TXA2), and thrombin. These agonists amplify 
the initial signals and recruit additional platelets from the 
circulation into a growing thrombus. The amplification of 
platelet activation and recruitment is mediated by G protein 
coupled receptors (GPCRs), such as the ADP receptors 
P2Y1 and P2Y12 (coupled to Gq and Gi, respectively), the 
TXA2 receptor Tp (coupled to Gq and G12/13) and PARs, 
which bind thrombin (coupled to Gi, Gq and G12/13) [2]. 
The functions and downstream signals of these platelet ad-
hesive receptors in hemostasis and thrombosis have been 
well characterized. However, the currently most widely 
used anti-platelet drugs, such as the antagonists of IIb3 
and P2Y12, target on the activation mechanisms and have 
low efficacy in many patients and are associated with seri-
ous bleeding side-effects. To develop more effective anti- 
thrombotic drugs, understanding how platelet activation is 
regulated is necessary.  
The accumulated evidence over the past decade indicates 
that endogenous receptor-mediated inhibitory mechanisms 
keep platelets quiescent and prevent excessive platelet acti-
vation. In this review, we discuss the mechanisms and ther-
apeutic potential of inhibitory pathways in the regulation of 
platelet activation. 
1  Inhibitory immunoglobulin superfamily 
(IgSF) 
IgSF proteins have been reported to be expressed on the 
plasma membranes of platelet and to regulate platelet adhe-
sion, aggregation and secretion. Among the IgSFs, platelet 
collagen receptor GPVI initiates platelet activating signals 
by binding to the immunoreceptor tyrosine-based activation 
motif (ITAM) of the Fc receptor -chain (FcR-chain) when 
platelets become tethered to the collagen and laminin pro-
teins of the exposed subendothelial matrix. The GPVI/ 
FcR-chain complex disseminates powerful signals, causing 
IIb3 activation and platelet secretion and aggregation. In 
addition, IgSFs also include C-type lectin-like receptor 2 
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(CLEC-2), which mediate hemITAM signaling [3].  
In addition to the activation mechanisms mentioned 
above, platelets also express IgSF inhibitory receptors, such 
as platelet endothelial cell adhesion molecule-1 
(PECAM-1), G6B, and carcinoembryonic antigen-related 
cell adhesion molecule 1 and 2 (CEACAM1 and 2) [4]. 
Their cytoplasmic domains bearing immunoreceptor tyro-
sine-based inhibitory motifs (ITIMs) have the capacity to 
bind multiple phosphatases, including SHP-1 and SHP-2, to 
attenuate cell signals; thus, they negatively regulate 
GPVI/FcR chain and CLEC-2-mediated platelet activation. 
In addition to the phosphatases SHP-1 and SHP-2, our study 
revealed that phosphatase and tensin homolog (PTEN), a 
negative regulator of phosphoinositide 3-kinase (PI3K) 
pathways, inhibits GPVI/FcR-chain-mediated platelet ac-
tivation via its inositol phospholipid phosphatase and tyro-
sine phosphatase functions [5]. 
Our group also recently found that ITIMs bearing paired 
immunoglobulin-like receptor B (PIRB) and its human 
ortholog leukocyte immunoglobulin-like receptor B2 
(LILRB2) were highly expressed in mouse and human 
platelets, respectively [6]. Deletion of the PIRB intracellular 
domain significantly facilitates agonist-induced mouse 
platelet aggregation and platelet spreading on immobilized 
fibrinogen. Characterization of the signaling involved in this 
process indicated that PIRB associates with tyrosine phos-
phatases SHP1/2 and attenuates tyrosine phosphorylation of 
the linker for activation of T cells (LAT) signalosome, in-
tegrin 3 and its downstream focal adhesion kinase (FAK) 
to inhibit platelet activation. Of particular interest, we found 
that PIRB/LILRB2 potential ligand angiopoietin-like-  
protein 2 (ANGPTL2) is expressed and stored in platelet 
-granules and is released upon platelet activation to inhibit 
agonist-induced platelet activation [6]. Therefore, our study 
reveals a new self-control mechanism for the negative reg-
ulation of platelet activation and a new antithrombotic ther-
apeutic target, the ANGPTL2/PIRB pathway [7]. 
2  Inhibitory nuclear receptors 
Recently, several intracellular receptors, such as the liver X 
receptor (LXR), retinoid X receptor (RXR), peroxisome 
proliferator activated receptor  (PPAR) and glucocorticoid 
receptor (GR) [8], have been shown to be expressed in 
platelets. Although intracellular receptors in anucleated 
platelets seem unnecessary, agonists to RXR, LXR, PPAR 
and GR significantly interfere with platelet function in a 
nongenetic manner. 
Retinoid X receptors (RXRs) are important transcrip-
tional nuclear hormone receptors. Human platelets express 
RXR and RXR. RXR ligands exert an inhibitory effect 
on platelet aggregation mediated by ADP and the TXA2 
receptors, but only weakly on that by collagen receptor. An 
RXR can bind to Gq, thereby, inhibit Gq coupled recep-
tor-induced Rac activation and intracellular calcium release.  
The peroxisome proliferator-activated receptors (PPARs) 
consist three nuclear receptor isoforms (,/, and ) and 
associates with the retinoic X receptor (RXR). PPAR is 
expressed in human platelets, and its ligands significantly 
inhibit platelet aggregation in vitro and thrombus formation 
in vivo. After platelet activation, PPAR associates with Syk 
and LAT, which are downstream signaling molecules of the 
collagen receptor GPVI, indicating a potential mechanism 
of PPAR in the negative regulation of GPVI-mediated sig-
naling. Of particular interest statins, which are cholester-
ol-lowering drugs, inhibit platelet activation by engaging 
PPAR and PPAR. 
Liver X receptors (LXRs) are transcription factors that 
are involved in the regulation of cholesterol homeostasis. 
Dr. Gibbin’s group [8] recently showed that LXR- is pre-
sent in human platelets and that the LXR ligands GW3965 
and T0901317 suppress platelet aggregation stimulated by 
agonists. Mechanism analysis revealed that active LXR was 
able to associate with signaling components of the collagen 
receptor GPVI, resulting in an inhibition of platelet activa-
tion. 
Glucocorticoid receptor (GR) was also identified in hu-
man platelets, and the GR ligand prednisolone extensively 
reduces ADP and TXA2 receptor-mediated platelet aggre-
gation. The antithrombotic effects of nuclear receptor lig-
ands further indicate that nuclear receptors are potential 
targets for the prevention of athero-thrombotic disease.  
3  Inhibitory prostanoid receptors 
Prostanoids are a family of metabolic derivatives of a satu-
rated fatty acid or prostanoic acid and play critical roles in 
the platelet-vascular wall interaction. Several enzymes, such 
as phospholipase A2, cyclooxygenases (COXs) and tissue 
specific enzymes, are involved in the synthesis of pros-
tanoids. There are a variety of prostanoids, such as throm-
boxane A2 (TXA2), prostaglandin E2 (PGE2), prostacyclin 
(PGI2), and prostaglandin D [9]. 
TXA2, the major prostanoid product in platelets, is a po-
tent stimulator of platelet aggregation via activation of a 
TXA2-specific GPCR receptor (TP). In atherosclerotic 
plaques, prostaglandin H2 (PGH2) is preferentially con-
verted into PGE2 by active macrophages. Macro-
phage-derived PGE2 can be released to activate EP3 recep-
tors on platelets, which exacerbates arterial thrombosis. 
Aspirin irreversibly inhibits platelet cyclooxygenase 1 pre-
venting the formation of PGH2 and, therefore, TXA2. 
In contrast, PGI2, the major prostanoid product of the 
macrovascular endothelium, has an intensively inhibitory 
function via the modulation of platelet intracellular cyclic 
nucleotide levels [10]. PGI2 binds to its Gs coupled recep-
tor, IP, and elevates the intracellular levels of cAMP. As a 
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result, the activity of protein kinase A (PKA) is elevated, 
which inhibits platelet activation by directly suppressing 
activation signals mediated by Gi coupled receptors, such as 
P2Y12, TP and the PGE2 receptor EP3. Similarly, the pros-
taglandin D receptor DP1 and the PGE2 receptors EP2 and 
EP4 are coupled to Gs and are highly expressed in plate-
lets. Activation of DP1, EP2 and EP4 results in inhibition of 
platelet activation. 
The reciprocal regulation of platelet function by endog-
enous prostanoids and their activating and inhibitory pros-
tanoid receptors brings new insight into the regulation of 
platelet functions. And high selective ligands of inhibitory 
prostanoid receptors can be developed as a new class of 
antiplatelet reagents. 
In summary, there naturally exist a variety of inhibitory 
receptors, which are critical for the regulation of platelet 
activation. Functional cross-talk between endogenous acti-
vating and inhibitory mechanisms generate networks that 
maintain platelet homeostasis. The most commonly used 
anti-platelet drugs targeting activation mechanism have low 
efficacies in many patients and cause serious bleeding 
side-effects. Excitation of endogenous inhibitory mecha-
nism in platelets may bring hope to the development of 
more reliable therapeutic approaches to thrombotic diseases. 
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